Rett Syndrome - Therapeutics Development
Latest Pharmaceutical and Healthcare disease pipeline guide Rett Syndrome - Pipeline Review, H1 2017, provides an overview of the Rett Syndrome (Central Nervous System) pipeline landscape.
Summery
Rett syndrome is a neurodevelopmental disorder. This is caused by genetic mutation on MECP2 gene.
Rett syndrome is described in four stages: Stage I or early onset, Stage II or rapid destruction, Stage
III, or the plateau and Stage IV, or the late motor deterioration stage.
Symptoms include slowed growth, loss of normal movement and coordination, loss
of communication abilities, breathing problems, pain, irregular heartbeat and
seizures. Risk factors include family history and gender. Treatment includes
disease modifying drugs.
Report Highlights
·
The Pharmaceutical and Healthcare latest pipeline guide Rett
Syndrome - Pipeline Review, H1 2017, provides comprehensive information on the
therapeutics under development for Rett Syndrome (Central Nervous System),
complete with analysis by stage of development, drug target, mechanism of
action (MoA), route of administration (RoA) and molecule type. The guide covers
the descriptive pharmacological action of the therapeutics, its complete
research and development history and latest news and press releases.
·
The Rett Syndrome (Central Nervous System) pipeline guide
also reviews of key players involved in therapeutic development for Rett
Syndrome and features dormant and discontinued projects. The guide covers
therapeutics under Development by Companies /Universities /Institutes, the
molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical
and Discovery stages are 1, 4, 7, 6 and 3 respectively. Similarly, the
Universities portfolio in Preclinical stages comprises 3 molecules,
respectively.
·
Rett Syndrome (Central Nervous System) pipeline guide helps
in identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create effective
counter strategies to gain competitive advantage. The guide is built using data
and information sourced from Global Markets Direct’s proprietary databases, company/university
websites, clinical trial registries, conferences, SEC filings, investor
presentations and featured press releases from company/university sites and
industry-specific third party sources. Additionally, various dynamic tracking
processes ensure that the most recent developments are captured on a real time
basis.
Scope
·
The pipeline guide provides a snapshot of the global
therapeutic landscape of Rett Syndrome (Central Nervous System).
·
The pipeline guide reviews pipeline therapeutics for Rett
Syndrome (Central Nervous System) by companies and universities/research
institutes based on information derived from company and industry-specific
sources.
·
The pipeline guide covers pipeline products based on several
stages of development ranging from pre-registration till discovery and
undisclosed stages.
·
The pipeline guide features descriptive drug profiles for the
pipeline products which comprise, product description, descriptive licensing
and collaboration details, R&D brief, MoA & other developmental
activities.
·
The pipeline guide reviews key companies involved in Rett
Syndrome (Central Nervous System) therapeutics and enlists all their major and
minor projects.
·
The pipeline guide evaluates Rett Syndrome (Central Nervous
System) therapeutics based on mechanism of action (MoA), drug target, route of
administration (RoA) and molecule type.
·
The pipeline guide encapsulates all the dormant and
discontinued pipeline projects.
·
The pipeline guide reviews latest news related to pipeline
therapeutics for Rett Syndrome (Central Nervous System)
Reasons to buy
·
Procure strategically important competitor information,
analysis, and insights to formulate effective R&D strategies.
·
Recognize emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage.
·
Classify potential new clients or partners in the target
demographic.
·
Develop tactical initiatives by understanding the focus areas
of leading companies.
·
Plan mergers and acquisitions meritoriously by identifying
key players and it’s most promising pipeline therapeutics.
·
Formulate corrective measures for pipeline projects by
understanding Rett Syndrome (Central Nervous System) pipeline depth and focus
of Indication therapeutics.
·
Develop and design in-licensing and out-licensing strategies
by identifying prospective partners with the most attractive projects to
enhance and expand business potential and Scope.
·
Adjust the therapeutic portfolio by recognizing discontinued
projects and understand from the know-how what drove them from pipeline.
Category of Report:
Related
Reports:
Contact Details:
Aarkstore Enterprise
Phone: +91 - 22 2756 4963
24/7 Online Support: +91 9987295242
Email: contact@aarkstore.com
Phone: +91 - 22 2756 4963
24/7 Online Support: +91 9987295242
Email: contact@aarkstore.com
Our website: https://www.aarkstore.com
Comments
Post a Comment